Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
14.90B
Market cap14.90B
Price-Earnings ratio
25.39
Price-Earnings ratio25.39
Dividend yield
Dividend yield
Average volume
938.06K
Average volume938.06K
High today
High today
Low today
Low today
Open price
$240.00
Open price$240.00
Volume
0.00
Volume0.00
52 Week high
$250.74
52 Week high$250.74
52 Week low
$150.89
52 Week low$150.89

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $238.67, giving the company a market capitalization of 14.9B. It carries a P/E multiple of 25.39.

During the trading day, Ascendis Pharma A/S(ASND) stock saw an opening price of $240.00, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 938.06K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $250.74 and a low of $150.89.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $250.74 and a low of $150.89.

ASND News

TipRanks 1d
Ascendis Pharma price target raised to $345 from $342 at Barclays

Barclays raised the firm’s price target on Ascendis Pharma (ASND) to $345 from $342 and keeps an Overweight rating on the shares post the Q1 report. The company...

TipRanks 4d
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count

Ascendis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterate...

TipRanks 5d
Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

100%

of 17 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.